Immune checkpoint blockade has contributed to the efficacy of targeted anti‐programmed death 1 (PD‐1)/anti‐programmed death‐ligand 1 (PD‐L1) agents in many tumor types, with clinical responses observed in a small proportion of patients with Hodgkin lymphoma (HL) and rare non‐HL (NHL) subtypes.1, 2. This evidence concerns the gene CD274 and Hodgkins lymphoma.